News NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with ATTR polyneuropathy
News AZ, Ionis get CHMP backing for ATTR polyneuropathy drug AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines
News Lilly unveils employer scheme for weight-loss drug Zepbound Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
